相关实验视频

Updated: May 30, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

一个开放的标签,abemaciclib与paclitaxel的IB/II期研究,用于CDK4/6通路基因组改变的瘤

K H Kim¹, C Park², S-H Beom¹

¹Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.

|January 28, 2025

概括

阿贝马西克利布与帕克利塔塞尔结合,对CDK4/6-激活瘤显示出中度的临床益处. 一个绕道信号通路激活的子组经历了较差的无进展生存率.

科学领域:

在瘤学瘤学.
癌症生物学癌症生物学
药理学药理学是指药理学的学科.

背景情况:

循环D依赖激酶 (CDK),特别是CDK4/6,在癌细胞通过异常蛋白质酸化扩散中至关重要.
向CDK4/6是一种治疗CDK4/6-激活瘤的策略.

研究的目的:

评估abemaciclib与帕克利塔塞尔联合治疗CDK4/6-激活固体瘤患者的疗效和安全性.
为了确定潜在的生物标志物预测治疗反应.

主要方法:

进行了一项开放的,单臂的Ib/II期试验.
患者在4周周期内接受abemaciclib (100毫克每天两次) 和paclitaxel (70毫克/m2在1,8,15天).
评估了整体反应率 (ORR),临床益处率 (CBR),无进展生存率 (PFS),整体生存率 (OS) 和安全性. 基因分析包括下一代测序和循环瘤DNA.

主要成果:

该研究包括30名患者,其中27人在疗效分析中. CDK4/6和CCND1/3放大是常见的.
该ORR为7.4%,而CBR为66.7%. 中位数PFS为3.5个月,中位数OS为9.9个月.
一个"遗传状况不佳"的子组 (RAS,Wnt,PI3K,NOTCH突变和/或CCNE放大) 显示PFS明显较差.

结论:

在CDK4/6-激活瘤中,Abemaciclib加上帕克利塔塞尔显示出中度的临床益处.
绕道信号通路激活和CCNE放大定义了一个对治疗结果产生负面影响的子组.
未来的研究应该集中在同质的患者群体上,以验证这些发现.

关键词:

在CDK4/6中使用.一个有着巨大的力量.帕克利塔克塞尔 (paclitaxel) 是一种药物.

更多相关视频

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...